^
Association details:
Biomarker:NPM1 mutation
Cancer:Acute Myelogenous Leukemia
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

FREQUENCY AND STIMULATION OF NPM1-SPECIFIC IMMUNE RESPONSES BY ANTI-PD1 ANTI-BODIES IN NPM1-MUTATED AML

Published date:
05/12/2021
Excerpt:
In NPM1mut AML pts 9/15 (60%) showed immune responses against all four epitopes...the immune effect in NPM1mut patients increased markedly with the epitope NPM1 and even more when anti-PD-1 was added to CFI, with a mean reduction of 47%. All 15 showed a reduction with anti-PD1, even those that did not show any reduction with the epitope NPM1 alone.